Literature DB >> 7476843

Increasing morbidity and mortality associated with abuse of methamphetamine--United States, 1991-1994.

.   

Abstract

Methamphetamine (also known as "speed," "crystal," "crank," "go," and "ice") is the most widely illegally manufactured, distributed, and abused type of amphetamine, a class of stimulant drugs. An estimated 4 million persons in the United States have abused methamphetamine at least once (1). Information from several sources--including medical examiners, hospital emergency departments (EDs), substance-abuse-treatment facilities, and community epidemiologists--suggests a recent increase in morbidity and mortality associated with abuse of methamphetamine in the United States, primarily in the West but also in the South and Midwest. To characterize trends in methamphetamine-associated morbidity and mortality during 1991-1994, the Substance Abuse and Mental Health Services Administration (SAMHSA) compiled and analyzed data from the Drug Abuse Warning Network (DAWN) and the Treatment Episode Data Set (TEDS). This report summarizes the results of these analyses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7476843

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  12 in total

1.  Psychostimulant dependence in a community sample.

Authors:  Li-Tzy Wu; William E Schlenger
Journal:  Subst Use Misuse       Date:  2003-01       Impact factor: 2.164

2.  Injection drug use among stimulant users in a national sample.

Authors:  Li-Tzy Wu; Daniel J Pilowsky; Wendee M Wechsberg; William E Schlenger
Journal:  Am J Drug Alcohol Abuse       Date:  2004       Impact factor: 3.829

3.  Crystal methamphetamine use among American Indian and White youth in Appalachia: Social context, masculinity, and desistance.

Authors:  Ryan A Brown
Journal:  Addict Res Theory       Date:  2010-06

4.  Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.

Authors:  Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki
Journal:  Addiction       Date:  2017-08-29       Impact factor: 6.526

5.  Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men.

Authors:  Moupali Das; Deirdre Santos; Tim Matheson; Glenn-Milo Santos; Priscilla Chu; Eric Vittinghoff; Steve Shoptaw; Grant N Colfax
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

Review 6.  Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  AAPS J       Date:  2007-01-05       Impact factor: 4.009

7.  Detection of stimulant drugs of abuse in maternal and neonatal hair.

Authors:  Facundo Garcia-Bournissen; Ben Rokach; Tatyana Karaskov; Joey Gareri; Gideon Koren
Journal:  Forensic Sci Med Pathol       Date:  2007-09-05       Impact factor: 2.007

8.  Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996-2003.

Authors:  Moupali Das-Douglas; Grant Colfax; Andrew R Moss; David R Bangsberg; Judith A Hahn
Journal:  J Urban Health       Date:  2007-12-27       Impact factor: 3.671

Review 9.  Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

10.  Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes.

Authors:  Mikhail A Gavrilin; Lawrence E Mathes; Michael Podell
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.